Lumenis Launches Aluma™ Skin Renewal System with FACES™

Yokneam, Israel, October 12, 2005 – Lumenis^® Ltd. (LUME.PK), a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications, announced today the launch of its revolutionary new Aluma™ Skin Renewal System with FACES™ (Functional Aspiration Controlled Electrothermal Stimulation) technology at the EADV (European Academy of Dermatology and Venereology). The Aluma is the first system to offer predictable and virtually painless non-invasive treatment of fine lines, wrinkles and skin laxity.

“What makes this product so exciting is that unlike older technologies, our Aluma treatment is predictable and comfortable. The population is aging, and the market for effective, “no downtime” procedures to treat wrinkles and fine lines, is vast and largely unmet,” commented Avner Raz, Lumenis President and CEO. “With the Aluma system, Lumenis is uniquely positioned to offer physicians the full continuum of treatment for their patients with sun-damaged and photoaged skin. From microdermabrasion and IPL®, to Aluma Skin Renewal, as well as microablation and skin resurfacing – Lumenis offers it all.”

Aluma’s FACES technology is truly a breakthrough approach to treatment. The vacuum-assisted and bipolar radio-frequency handpiece conforms to the skin to allow the energy to safely bypass the epidermis and places the dermis directly in line with the beam of energy. RF energy is deposited deep within the dermis, creating a uniform and contained zone of heating, which results in collagen contraction and renewal with little to no discomfort. A treatment typically takes only 15 minutes and patients can immediately return to work and their normal daily activities.

In a safety and efficacy study of 46 patients treated around the eyes and mouth “everyone achieved at least a 50% improvement,” said study coauthor Dr. Michael Gold of Nashville, Tennessee. “Patient satisfaction was high, with over 90% of the patients satisfied.” Dr. Mitchel Goldman of La Jolla, California, the study’s other author added, “Treatments are very fast and require no topical anesthetics. I like the Aluma for treating the neck, and it usually takes only five minutes, as do other individual areas,” continued Dr. Goldman. “Furthermore, the Aluma is effective in nearly every patient, unlike some other RF techniques that are only efficacious in certain patients. I believe the Aluma is the next generation of radio frequency treatment.”

The Aluma will be launched in Europe at the European Academy of Dermatology and Venereology (EADV) meeting on October 12th. Launches in Japan and China / Asia Pacific will take place in November and December, respectively. FDA clearance is pending in the U.S.

Lumenis is a global developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications. The Company offers a wide range of products along with extensive product support systems including training, education and service. Lumenis invests heavily in research and development to maintain and enhance its leading industry position. The Company holds numerous patents worldwide on its technologies. For more information about Lumenis and its products, log onto www.lumenis.com.


Contact:

Lauri Hanover, CFO
1-866-232-6803
+972-4-959-9122

The statements in this press release that are not historical facts are forward-looking statements that are subject to risks and uncertainties. The Company's actual results could differ materially from those anticipated in the forward looking statements based on a variety of factors, including, among others: uncertainties with respect to market acceptance of the Company's products, the implementation and outcome of its Turnaround Plan, obtaining regulatory approvals for new products or for the sale of existing products in new markets and enforcement of intellectual property rights; risks associated with competition and competitive pricing pressures, economic conditions generally, the Company's international operations and the Company's ability to integrate its operations with those of acquired businesses; the outcome of the Securities and Exchange Commission investigation and several securities class action lawsuits to which the Company is subject and the outcome of the investigation conducted by the Audit Committee; uncertainties relating to the Company’s continuing liquidity; and other risks detailed from time to time in the reports filed by Lumenis with the SEC, including its annual report on Form 10-K and quarterly reports on Form 10-Q.